🔥🐔 BizChicken 🐔🔥

Companies Similar to Royalty Pharma plc

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Royalty Pharma plc

Royalty Pharma plc logo
Market Cap: Highest
Employees: Low

biopharmaceutical royalties

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry, collaborating with various partners to acquire royalties on marketed and development-stage therapies in multiple therapeutic areas.

Tags: biopharmaceutical, healthcare, innovation, royalties, therapies

Symbol: RPRX

Recent Price: $25.32

Industry: Biotechnology

CEO: Mr. Pablo Gerardo Legorreta

Sector: Healthcare

Employees: 75

Address: 110 East 59th Street, New York, NY 10022

Phone: 212 883 0200

Last updated: 2024-12-31

Royalty Management Holding Corporation

Royalty Management Holding Corporation logo
Market Cap: Lowest
Employees: Not Available

N/A

Royalty Management Holding Corporation operates as a royalty company that identifies and invests in undervalued assets. It acquires and invests in natural resources, patents, intellectual property, and digital assets. The company was founded in 2021 and is based in Fishers, Indiana.

No tags available.

Symbol: RMCO

Recent Price: $1.01

Industry: Asset Management

CEO: Mr. Thomas M. Sauve

Sector: Financial Services

Employees: N/A

Address: 12115 Visionary Way, Fishers, IN 46038

Phone: (317) 855-9926

Last updated: 2024-12-31

Eli Lilly and Company

Eli Lilly and Company logo
Market Cap: Highest
Employees: Highest

Pharmaceuticals

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, specializing in treatments for diabetes, cancer, and other conditions.

Tags: Biotechnology, Cancer Treatment, Diabetes, Pharmaceuticals

Symbol: LLY

Recent Price: $773.84

Industry: Drug Manufacturers - General

CEO: Mr. David A. Ricks

Sector: Healthcare

Employees: 43000

Address: Lilly Corporate Center, Indianapolis, IN 46285

Phone: 317 276 2000

Last updated: 2024-12-31

Pfizer Inc.

Pfizer Inc. logo
Market Cap: Highest
Employees: Highest

biopharmaceutical products

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, offering medicines and vaccines across various therapeutic areas.

Tags: COVID-19, biopharmaceuticals, biosimilars, medicines, therapeutic areas, vaccines

Symbol: PFE

Recent Price: $26.42

Industry: Drug Manufacturers - General

CEO: Dr. Albert Bourla D.V.M., Ph.D.

Sector: Healthcare

Employees: 88000

Address: 235 East 42nd Street, New York, NY 10017

Phone: 212 733 2323

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

Coya Therapeutics, Inc.

Coya Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

COYA 101

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs), focusing on enhancing biologics and therapies for neurodegenerative and autoimmune diseases.

Tags: Tregs, autoimmune diseases, biotechnology, neurodegenerative diseases, therapy

Symbol: COYA

Recent Price: $5.81

Industry: Biotechnology

CEO: Dr. Howard Berman Ph.D.

Sector: Healthcare

Employees: 8

Address: 5850 San Felipe Street, Houston, TX 77057

Phone: 800-587-8170

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

Fortress Biotech, Inc.

Fortress Biotech, Inc. logo
Market Cap: Lowest
Employees: Low

Pharmaceutical and Biotechnology Products

Fortress Biotech, Inc., is a biopharmaceutical company focused on developing and commercializing a range of dermatology products and late-stage product candidates for various medical conditions.

Tags: Menkes disease, NSCLC, acne treatment, amyloidosis, biopharmaceutical, biotechnology, cancer treatment, dermatology, immunodeficiency, pain management, pharmaceutical, vaccines

Symbol: FBIO

Recent Price: $2.18

Industry: Biotechnology

CEO: Dr. Lindsay Allan Rosenwald

Sector: Healthcare

Employees: 186

Address: 1111 Kane Concourse, Bay Harbor Islands, FL 33154

Phone: 781 652 4500

Leadership

  • Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer
  • Michael S. Weiss, Executive Vice Chairman, Strategic Development
  • David Jin, Chief Financial Officer and Head of Corporate Development
  • George Avgerinos, Ph.D., Senior Vice President, Biologics Operations
  • Samuel Berry, General Counsel and Corporate Secretary
  • Jimmie Harvey, Jr., M.D., Director
  • Malcolm Hoenlein, Director
  • Dov Klein, Director
  • J. Jay Lobell, Director
  • Kevin L. Lorenz, J.D., Director
  • Lucy Lu, M.D., Director

Last updated: 2024-12-31

Lumos Pharma, Inc.

Lumos Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

LUM-201

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.

Tags: biopharmaceutical, clinical trial, growth hormone, rare diseases, therapeutics

Symbol: LUMO

Recent Price: $4.34

Industry: Biotechnology

CEO: Mr. Richard J. Hawkins

Sector: Healthcare

Employees: 33

Address: 4200 Marathon Boulevard, Austin, TX 78756

Phone: 512 215 2630

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

Repligen Corporation

Repligen Corporation logo
Market Cap: Highest
Employees: High

bioprocessing technologies and systems

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing worldwide, offering products like Protein A ligands, chromatography columns, ELISA test kits, and filtration products.

Tags: ELISA test kits, Protein A ligands, biologics purification, bioprocessing, chromatography, filtration systems

Symbol: RGEN

Recent Price: $143.81

Industry: Medical - Instruments & Supplies

CEO: Mr. Olivier Loeillot

Sector: Healthcare

Employees: 1783

Address: Building 1, Waltham, MA 02453

Phone: 781 250 0111

Leadership

  • Mark A. Gambino, President and CEO
  • Pradeep K. Gohil, Chief Financial Officer
  • Matthew B. Wrobel, Chief Technology Officer
  • Claudia A. Grunewald, Director of Quality Assurance
  • Mickey R. Perry, Chief Operating Officer
  • Paul C. Miller, General Counsel and Secretary
  • James J. O'Brien, Chairman of the Board
  • Diane Williams, Board Member
  • Charles A. Jamieson, Board Member
  • Rebecca D. Faulkner, Board Member

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

Rallybio Corporation

Rallybio Corporation logo
Market Cap: Lowest
Employees: Lowest

RLYB212

Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.

Tags: biotechnology, clinical trials, monoclonal antibodies, rare diseases, therapeutics

Symbol: RLYB

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Stephen Uden M.B, M.D.

Sector: Healthcare

Employees: 25

Address: 234 Church Street, New Haven, CT 06510

Phone: 203 859 3820

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

XOMA Corporation

XOMA Corporation logo
Market Cap: Low
Employees: Lowest

Pre-commercial therapeutic candidates

XOMA Corporation operates as a biotechnology royalty aggregator focusing on enhancing human health by acquiring potential future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotech companies. With a portfolio of approximately 70 assets, it focuses on early to mid-stage clinical assets with commercial sales potential.

Tags: Biotechnology, Clinical Assets, Pharmaceutical, Royalty Aggregator, Therapeutic Candidates

Symbol: XOMA

Recent Price: $26.09

Industry: Biotechnology

CEO: Mr. Owen P. Hughes Jr.

Sector: Healthcare

Employees: 13

Address: 2200 Powell Street, EmeryVille, CA 94608

Phone: 510 204 7200

Last updated: 2024-12-31